Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
The Group operates with our company at its core, centered on the pharmaceutical business, and includes 8 consolidated subsidiaries, 1 equity-method affiliate and 1 other affiliate. Its principal activities are the manufacture, procurement and sale of prescription pharmaceuticals, regenerative medicine products and pharmaceutical raw materials. Group companies collaborate across business functions in areas including procurement, facilities management, market research, outsourcing related to clinical trials, development and licensing. The principal affiliates are as follows:
- クロマテック (Nishinomiya, Hyogo Prefecture; capital of ¥10 million; 100.0% voting rights), among others.
- ＪＣＲエンジニアリング (Nishi Ward, Hyogo Prefecture; capital of ¥10 million; 100.0% voting rights), among others.
- JCR International S.A. (Fribourg, Switzerland; capital of CHF 1 million; 100.0% voting rights), among others.
- JCR USA, Inc. (San Diego, United States; capital of US$5 million; 65.0% voting rights), among others.
- ArmaGen, Inc. (San Diego, United States; capital of US$1; 100.0%), among others.
- JCR Do Brasil FarmacÊuticos Importação e Exportação Ltda. (Caieiras, Brazil; capital of BRL 10 million; 100.0%), among others.
- JCR Luxembourg S.A. (Dudelange, Luxembourg; capital of €1 million; 100.0%), among others.
- JCR Europe B.V. (Leiden, the Netherlands; capital of €500,000; 100.0%), among others.
- AlliedCel Corporation (Chuo Ward, Kobe; capital of ¥700 million; 50.0% voting rights), among others.
- Medipal Holdings (Chuo Ward, Tokyo; capital of ¥22,398 million; 23.8% equity interest), among others.
- Other affiliates, including equity-method affiliates.
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.